Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome

Published by Jon Henrik Laake on May 23, 2016

Disclaimer

Sponsors

Scandinavian Society of Anesthesiology and Intensive Care Medicine

Contact

Abstract

The objective of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI) task force on fluid and drug therapy in adults with acute respiratory distress syndrome (ARDS) was to provide clinically relevant, evidence-based treatment recommendations according to standards for trustworthy guidelines.

Language

en

PICOS

PICO 5.1

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Restrictive fluid therapy
Comparator
Liberal fluid therapy
Outcomes

PICO 5.2

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Corticosteroids at any dose or duration and route of administration
Comparator
Placebo or None
Outcomes

PICO 5.3

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Beta2 agonists at any dose or duration and route of administration
Comparator
Placebo or None
Outcomes

PICO 5.4

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Neuromuscular blocking agents (NMBAs) at any dose or duration
Comparator
Placebo or None
Outcomes

PICO 5.5

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Inhaled nitric oxide (iNO)
Comparator
Placebo or None
Outcomes

PICO 5.6

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Prostanoids at any dose and any route of administration
Comparator
Placebo or None
Outcomes

PICO 5.7

Population
Mechanically ventilated adults with acute respiratory distress syndrome (ARDS)
Intervention
Statins in any dose or route of administration
Comparator
Placebo or None
Outcomes